An observational mother–infant study examined maximum weight loss after birth. Its benzodiazepine analyses concerned an additional exposure within an opioid-exposed population.
The study included 868 dyads and considered additional prescription and toxicology exposures. It defined maximum percentage weight loss relative to birth weight during the birth hospitalization, up to fourteen days.
The overall benzodiazepine association was not statistically significant. In smoking-stratified analyses, the authors reported an association with greater maximum weight loss among smokers, illustrating that the reported pattern depended on the analysis.
Prescription fills and clinical records do not establish every ingestion, and smoking, illness, treatment, and other exposures can complicate comparisons. A subgroup finding needs its subgroup and uncertainty retained.
This was not a trial assigning prenatal benzodiazepines, nor a study of birth weight itself. It cannot establish that benzodiazepines independently caused a particular infant’s weight loss. Review feeding, withdrawal care, serial weights, and the full exposure history before attributing an individual outcome to one drug class.
Original analysis of the supplied journal article, identified as PMC13250200.